Shares of Mazor Robotics Ltd. (NASDAQ:MZOR) have been given a consensus recommendation of “Hold” by the ten brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $37.33.

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Mazor Robotics in a research note on Thursday, July 6th. Ladenburg Thalmann Financial Services reissued a “buy” rating and set a $46.00 price target on shares of Mazor Robotics in a report on Monday, June 12th. Finally, Zacks Investment Research downgraded Mazor Robotics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 18th.

Shares of Mazor Robotics (NASDAQ:MZOR) traded down 2.57% during midday trading on Friday, reaching $48.98. The company had a trading volume of 361,618 shares. Mazor Robotics has a 1-year low of $20.19 and a 1-year high of $51.49. The company’s 50-day moving average is $44.17 and its 200-day moving average is $37.88. The stock’s market capitalization is $1.18 billion.

Mazor Robotics (NASDAQ:MZOR) last issued its earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative net margin of 37.66% and a negative return on equity of 28.51%. The company had revenue of $15.46 million for the quarter, compared to analysts’ expectations of $15.38 million. During the same quarter last year, the company posted ($0.09) earnings per share. The firm’s quarterly revenue was up 86.7% on a year-over-year basis. On average, equities research analysts forecast that Mazor Robotics will post ($0.74) EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MZOR. Dimensional Fund Advisors LP boosted its stake in shares of Mazor Robotics by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 8,570 shares of the medical instruments supplier’s stock worth $296,000 after acquiring an additional 641 shares during the last quarter. Royal Bank of Canada grew its position in shares of Mazor Robotics by 9.2% during the 2nd quarter. Royal Bank of Canada now owns 21,663 shares of the medical instruments supplier’s stock valued at $749,000 after acquiring an additional 1,819 shares during the period. UBS Group AG grew its position in shares of Mazor Robotics by 2.4% during the 1st quarter. UBS Group AG now owns 99,954 shares of the medical instruments supplier’s stock valued at $2,976,000 after acquiring an additional 2,379 shares during the period. Quantbot Technologies LP bought a new stake in shares of Mazor Robotics during the 2nd quarter valued at $135,000. Finally, JPMorgan Chase & Co. grew its position in shares of Mazor Robotics by 398.5% during the 1st quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after acquiring an additional 5,579 shares during the period. Institutional investors and hedge funds own 25.92% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/analysts-set-mazor-robotics-ltd-mzor-price-target-at-37-33/1606030.html.

Mazor Robotics Company Profile

Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.

Analyst Recommendations for Mazor Robotics (NASDAQ:MZOR)

Receive News & Ratings for Mazor Robotics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mazor Robotics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.